Incidence and transmission of respiratory syncytial virus in urban and rural South Africa, 2017-2018
- PMID: 38167333
- PMCID: PMC10761814
- DOI: 10.1038/s41467-023-44275-y
Incidence and transmission of respiratory syncytial virus in urban and rural South Africa, 2017-2018
Abstract
Data on respiratory syncytial virus (RSV) incidence and household transmission are limited. To describe RSV incidence and transmission, we conducted a prospective cohort study in rural and urban communities in South Africa over two seasons during 2017-2018. Nasopharyngeal swabs were collected twice-weekly for 10 months annually and tested for RSV using PCR. We tested 81,430 samples from 1,116 participants in 225 households (follow-up 90%). 32% (359/1116) of individuals had ≥1 RSV infection; 10% (37/359) had repeat infection during the same season, 33% (132/396) of infections were symptomatic, and 2% (9/396) sought medical care. Incidence was 47.2 infections/100 person-years and highest in children <5 years (78.3). Symptoms were commonest in individuals aged <12 and ≥65 years. Individuals 1-12 years accounted for 55% (134/242) of index cases. Household cumulative infection risk was 11%. On multivariable analysis, index cases with ≥2 symptoms and shedding duration >10 days were more likely to transmit; household contacts aged 1-4 years vs. ≥65 years were more likely to acquire infection. Within two South African communities, RSV attack rate was high, and most infections asymptomatic. Young children were more likely to introduce RSV into the home, and to be infected. Future studies should examine whether vaccines targeting children aged <12 years could reduce community transmission.
© 2024. The Author(s).
Conflict of interest statement
C.C. has received grant support from Sanofi Pasteur, US CDC, Welcome Trust, Programme for Applied Technologies in Health (PATH), Bill & Melinda Gates Foundation and South African Medical Research Council (SA-MRC). A.V.G has received grant support from CDC, ASLM/Africa CDC, SA-MRC, WHO Afro, Fleming Fund, WHO, Wellcome Trust. N.W. reports receiving grants from Sanofi Pasteur, US CDC and the Bill & Melinda Gates Foundation. N.A.M has received a grant to his institution from Pfizer to conduct research in patients with pneumonia. J.M. has received grant support from Sanofi Pasteur and PATH. M.C received the Robert Austrian Award sponsored by Pfizer as well as received funding as part of the South Africa-Pittsburgh Public Health Genomic Epidemiology (SAPPHGenE) training program and reports support for attending meetings and/or travel paid to the institution from Bill and Melinda Gates Foundation. Other authors declare no competing interests.
Figures
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
